PTPN22-IN-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PTPN22-IN-1  纯度: 98.01%

PTPN22-IN-1 是一种有效的 PTPN22 抑制剂 (IC50=1.4 µM; Ki=0.50 µM)。PTPN22-IN-1 对 PTPN22 的选择性是类似磷酸酶的 7-10 倍。PTPN22-IN-1 增强体内抗肿瘤免疫反应。

PTPN22-IN-1

PTPN22-IN-1 Chemical Structure

CAS No. : 2580935-57-3

规格 价格 是否有货 数量
5 mg ￥4000 In-stock
10 mg ￥6800 In-stock
25 mg ￥13500 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

PTPN22-IN-1 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus

生物活性

PTPN22-IN-1 is a potent PTPN22 inhibitor (IC50=1.4 µM; Ki=0.50 µM). PTPN22-IN-1 exhibits >7-10 fold selectivity for PTPN22 over similar phosphatases. PTPN22-IN-1 augments antitumor immune responses[1]. From WO2021007491A1 compound L-1.

体外研究
(In Vitro)

PTPN22-IN-1 (Compound L-1) (WT mice; intraperitoneally) significantly reduces MC38 tumor growth. PTPN22-IN-1 (syngeneic immunocompetent model; CT26 in Balb/c mice) shows similar antitumor effects[1].
Administration of L-l intraperitoneally at 10 mg/kg yielded an average AUC of 4.55 µM h and Cmax of 1.1 1 µM (Fig. 9d), which is more than twice of its Ki value[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

PTPN22-IN-1 (Compound L-1) (WT mice; intraperitoneally) significantly reduces MC38 tumor growth. PTPN22-IN-1 (syngeneic immunocompetent model; CT26 in Balb/c mice) shows similar antitumor effects[1].
Administration of L-l intraperitoneally at 10 mg/kg yielded an average AUC of 4.55 µM h and Cmax of 1.1 1 µM (Fig. 9d), which is more than twice of its Ki value[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

455.46

Formula

C26H21N3O5
CAS 号

2580935-57-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble or slightly soluble)
参考文献

  • [1]. Elizabeth Jaffee, et al. Targeting ptpn22 in cancer therapy. WO2021007491A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务